Image Source: Unsplash
An Introduction
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies in the munKNEE Psychedelic Compound Based Clinical-Stage Drug Stocks Portfolio with their stock performances MTD as of yesterday, in descending order, in the month of July, their areas of focus, and their latest news, analyses and commentary where available.
- Compass Pathways (CMPS): DOWN 8.1% MTD; UP 26.3% in July
- focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest news, analyses and commentary:
- GH Research (GHRS); DOWN 18.1% MTD; UP 6.3% in July
- focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- Latest news, analyses and commentary: None
- atai Life Sciences (ATAI): DOWN 21.3% MTD; UP 16.5% in July
- Mind Medicine (MNMD): DOWN 28.8% MTD; UP 28.4% in July
Summary
On average, the above 4 stocks are DOWN 19.0% MTD after having gone UP 17.5% in July.
More By This Author:
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
American Cannabis MSO Portfolio Bucked Trend: Up 4.6% Last Week
These 7 Semiconductor/AI-Related Portfolios Are Down 9%, On Average, So Far In August
.webp)
Comments
Log in or sign up to join the conversation.